Avelumab for Advanced Merkel Cell Carcinoma: Global Real-World Data on Patient Response and Survival

INTRODUCTION: Avelumab is a programmed cell death-ligand 1 (PD-L1) inhibitor approved by the Food and Drug Administration for advanced Merkel cell carcinoma (MCC). Studies conducted in real-world settings have shed light on its effectiveness and safety in clinical settings. AREAS COVERED: Real-world...

Descripción completa

Detalles Bibliográficos
Autores principales: Lohray, Rishabh, Verma, Kritin K, Wang, Leo L, Haynes, Dylan, Lewis, Daniel J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658947/
https://www.ncbi.nlm.nih.gov/pubmed/38021416
http://dx.doi.org/10.2147/POR.S398151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658947/
https://www.ncbi.nlm.nih.gov/pubmed/38021416
http://dx.doi.org/10.2147/POR.S398151

Ejemplares similares